{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:26:48Z","timestamp":1792790808609,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-701"],"award-info":[{"award-number":["CA209-701"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2022\/GNT2018514"],"award-info":[{"award-number":["2022\/GNT2018514"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015626","name":"melanoma institute australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of sydney medical foundation","id":[{"id":"https:\/\/ror.org\/0384j8v12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04158-9","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:04:09Z","timestamp":1769594649000},"page":"952-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8431-7557","authenticated-orcid":false,"given":"Lotte L.","family":"Hoeijmakers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-285X","authenticated-orcid":false,"given":"Petros","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9985-0753","authenticated-orcid":false,"given":"Steven C. M. A.","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene L. M.","family":"Reijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-3222","authenticated-orcid":false,"given":"Marta","family":"Lopez-Yurda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegien","family":"Broeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Torres Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-806X","authenticated-orcid":false,"given":"Robyn P. M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-9912","authenticated-orcid":false,"given":"Judith M.","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-0662","authenticated-orcid":false,"given":"Michel W.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5201-1411","authenticated-orcid":false,"given":"Jurriaan","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza A.","family":"Rozeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay G.","family":"Grijpink-Ongering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A. M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-5430","authenticated-orcid":false,"given":"Karijn P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-7892","authenticated-orcid":false,"given":"Geke A. P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-1323","authenticated-orcid":false,"given":"Jos A.","family":"van der Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-6002","authenticated-orcid":false,"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen J.","family":"Witkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Lijnsvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M. C.","family":"Klop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-012X","authenticated-orcid":false,"given":"Charlotte L.","family":"Zuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Bruining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahim","family":"Al-Mamgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-3132","authenticated-orcid":false,"given":"Kerwin F.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-1253","authenticated-orcid":false,"given":"Sydney","family":"Ch\u2019ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Colebatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-6657","authenticated-orcid":false,"given":"Maria","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-0181","authenticated-orcid":false,"given":"Andrew J.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"John B. A. G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8991-0013","authenticated-orcid":false,"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A.","family":"van de Wiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-6935","authenticated-orcid":false,"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-5846","authenticated-orcid":false,"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"4158_CR1","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4158_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813\u2013823 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4158_CR3","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4158_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos, J. L. et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat. Commun. 12, 7348 (2021).","journal-title":"Nat. Commun."},{"key":"4158_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"4158_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839\u20131844 (2020).","journal-title":"Nat. Med."},{"key":"4158_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","volume":"29","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat. Med. 29, 593\u2013604 (2023).","journal-title":"Nat. Med."},{"key":"4158_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4158_CR9","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382\u20131399 (2016).","journal-title":"Cancer Discov."},{"key":"4158_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655\u20131661 (2018).","journal-title":"Nat. Med."},{"key":"4158_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"4158_CR12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649\u20131654 (2018).","journal-title":"Nat. Med."},{"key":"4158_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948\u2013960 (2019).","journal-title":"Lancet Oncol."},{"key":"4158_CR14","doi-asserted-by":"publisher","first-page":"S1233","DOI":"10.1016\/j.annonc.2024.08.2283","volume":"35","author":"MW Lucas","year":"2024","unstructured":"Lucas, M. W. et al. LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: the NADINA trial. Ann. Oncol. 35, S1233\u2013S1234 (2024).","journal-title":"Ann. Oncol."},{"key":"4158_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"4158_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat. Med. 27, 256\u2013263 (2021).","journal-title":"Nat. Med."},{"key":"4158_CR17","first-page":"9503","volume":"37","author":"AM Menzies","year":"2019","unstructured":"Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 37, 9503 (2019).","journal-title":"Nat. Med."},{"key":"4158_CR18","doi-asserted-by":"publisher","first-page":"115141","DOI":"10.1016\/j.ejca.2024.115141","volume":"214","author":"ILM Reijers","year":"2025","unstructured":"Reijers, I. L. M. et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: comparison of 3-year data from PRADO and OpACIN-neo. Eur. J. Cancer 214, 115141 (2025).","journal-title":"Eur. J. Cancer"},{"key":"4158_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","volume":"34","author":"JM Versluis","year":"2023","unstructured":"Versluis, J. M. et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann. Oncol. 34, 420\u2013430 (2023).","journal-title":"Ann. Oncol."},{"key":"4158_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","volume":"157","author":"ILM Reijers","year":"2022","unstructured":"Reijers, I. L. M. et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA Surg. 157, 335\u2013342 (2022).","journal-title":"JAMA Surg."},{"key":"4158_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/bjs.11168","volume":"106","author":"B Schermers","year":"2019","unstructured":"Schermers, B. et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Br. J. Surg. 106, 519\u2013522 (2019).","journal-title":"Br. J. Surg."},{"key":"4158_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers, I. L. M. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat. Med. 28, 1178\u20131188 (2022).","journal-title":"Nat. Med."},{"key":"4158_CR23","doi-asserted-by":"publisher","first-page":"S1232","DOI":"10.1016\/j.annonc.2024.08.2282","volume":"35","author":"GV Long","year":"2024","unstructured":"Long, G. V. et al. LBA41 long-term survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Ann. Oncol. 35, S1232 (2024).","journal-title":"Ann. Oncol."},{"key":"4158_CR24","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff, M. T. et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann. Oncol. 29, 1861\u20131868 (2018).","journal-title":"Ann. Oncol."},{"key":"4158_CR25","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin. Cancer Res. 29, 3352\u20133361 (2023).","journal-title":"Clin. Cancer Res."},{"key":"4158_CR26","doi-asserted-by":"publisher","first-page":"S946","DOI":"10.1016\/j.annonc.2025.08.2229","volume":"36","author":"SP Patel","year":"2025","unstructured":"Patel, S. P. et al. 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801. Ann. Oncol. 36, S946\u2013S947 (2025).","journal-title":"Ann. Oncol."},{"key":"4158_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301\u2013309 (2021).","journal-title":"Nat. Med."},{"key":"4158_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok, J. D. et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 392, 11\u201322 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4158_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","volume":"18","author":"PA Ascierto","year":"2017","unstructured":"Ascierto, P. A. et al. Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 18, 611\u2013622 (2017).","journal-title":"Lancet Oncol."},{"key":"4158_CR30","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1245\/s10434-018-6691-3","volume":"25","author":"L Angka","year":"2018","unstructured":"Angka, L. et al. Natural killer cell IFN\u03b3 secretion is profoundly suppressed following colorectal cancer surgery. Ann. Surg. Oncol. 25, 3747\u20133754 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"4158_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1046\/j.1365-2362.2000.00622.x","volume":"30","author":"HA Leaver","year":"2000","unstructured":"Leaver, H. A., Craig, S. R., Yap, P. L. & Walker, W. S. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur. J. Clin. Invest. 30, 230\u2013238 (2000).","journal-title":"Eur. J. Clin. Invest."},{"key":"4158_CR32","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","volume":"8","author":"OJ van Not","year":"2022","unstructured":"van Not, O. J. et al. Association of immune-related adverse event management with survival in patients with advanced melanoma. JAMA Oncol. 8, 1794\u20131801 (2022).","journal-title":"JAMA Oncol."},{"key":"4158_CR33","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","volume":"42","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden, R. J. et al. Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials. J. Clin. Oncol. 42, 3713\u20133724 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4158_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114172","volume":"207","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden, R. J. et al. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur. J. Cancer 207, 114172 (2024).","journal-title":"Eur. J. Cancer"},{"key":"4158_CR35","doi-asserted-by":"publisher","first-page":"e20221952","DOI":"10.1084\/jem.20221952","volume":"220","author":"ILM Reijers","year":"2023","unstructured":"Reijers, I. L. M. et al. IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma. J. Exp. Med. 220, e20221952 (2023).","journal-title":"J. Exp. Med."},{"key":"4158_CR36","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"4158_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/1471-2105-15-182","volume":"15","author":"H Jiang","year":"2014","unstructured":"Jiang, H., Lei, R., Ding, S. W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinformatics 15, 182 (2014).","journal-title":"BMC Bioinformatics"},{"key":"4158_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4158_CR39","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/bioinformatics\/btac166","volume":"38","author":"GH Putri","year":"2022","unstructured":"Putri, G. H., Anders, S., Pyl, P. T., Pimanda, J. E. & Zanini, F. Analysing high-throughput sequencing data in Python with HTSeq 2.0. Bioinformatics 38, 2943\u20132945 (2022).","journal-title":"Bioinformatics"},{"key":"4158_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"4158_CR41","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels, P., Magnusson, M., Lundin, S. & K\u00e4ller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047\u20133048 (2016).","journal-title":"Bioinformatics"},{"key":"4158_CR42","doi-asserted-by":"publisher","first-page":"lqae031","DOI":"10.1093\/nargab\/lqae031","volume":"6","author":"F Hanssen","year":"2024","unstructured":"Hanssen, F. et al. Scalable and efficient DNA sequencing analysis on different compute infrastructures aiding variant discovery. NAR Genom. Bioinform. 6, lqae031 (2024).","journal-title":"NAR Genom. Bioinform."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04158-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04158-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04158-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:59Z","timestamp":1774018979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04158-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4158"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04158-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7090131\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No author has received financial support for the work on this paper, and no medical writer was involved at any stage of the preparation of this paper. A.M.M. has served on advisory boards for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Pierre Fabre and QBiotics. R.P.M.S. has received honoraria for advisory board participation from Merck Sharp & Dohme and Clinical Laboratories Pty Ltd. W.J.v.H. has received speaker\u02bcs honoraria from Regeneron Pharmaceuticals, Sanofi, Merck Sharp & Dohme, Belpharma and Novartis; reports an advisory role with Belpharma; and has received a research grant from Amgen. E.K. has consultancy\/advisory relationships with Delcath, Immunocore and Lilly and has received research grants unrelated to this paper from Bristol Myers Squibb, Delcath, Novartis and Pierre Fabre. These grants are unrelated to the present work and are paid to the institution. A.A.M.v.d.V. received travel fees from Ipsen and consultancy fees (all paid to the institution) from Bristol Myers Squibb, Merck Sharp & Dohme, Ipsen, Eisai, Pfizer, Novartis, Sanofi, Roche and Pierre Fabre. K.P.M.S. has consultancy\/advisory relationships with AbbVie and Sairopa; has received research funding from TigaTx, Bristol Myers Squibb, Philips, Genmab and Pierre Fabre; and has received honoraria from Bristol Myers Squibb (all paid to the institution). H.E. has received institutional research grants from SkyLineDx, Bristol Myers Squibb, Novartis and Pierre Fabre; a speaker honorarium from Janssen; and non-personal speaker honoraria (paid to the hospital) from Bristol Myers Squibb and Novartis. H.E. has also served on expert boards for Pierre Fabre and Bristol Myers Squibb. G.A.P.H. reports consultancy\/advisory relationships with Amgen, Bristol Myers Squibb, Roche, Merck Sharp & Dohme, Novartis, Sanofi and Pierre Fabre and receiving research grants from Bristol Myers Squibb and Seerave (all paid to the institution). S. Ch\u2019ng receives fees for professional services provided to Merck Sharp & Dohme and SkylineDx. J.B.A.G.H. reports advisory roles for Achilles Therapeutics, AstraZeneca, BioNTech, Bristol Myers Squibb, Immunocore, Instil Bio, Iovance Biotherapeutics, Ipsen, Molecular Partners, MSD Oncology, Neogene Therapeutics, Novartis, Roche\/Genentech, Sanofi, S\u0101stra, Third Rock Ventures and T-Knife; has received research funding (paid to the institution) from Amgen, Asher Biotherapeutics, BioNTech, Bristol Myers Squibb, Merck Sharp & Dohme, Neon Therapeutics and Novartis; and is a stockowner of Neogene Therapeutics and S\u0101stra. R.V.R. has received honoraria from Merck Sharp & Dohme. R.A.S. has received fees for professional services from SkylineDx, IO Biotech ApS, MetaOptima Technology, F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, QBiotics, Novartis, Merck Sharp & Dohme, NeraCare, Amgen, Bristol Myers Squibb, Myriad Genetics and GlaxoSmithKline. A.C.J.v.A. reports advisory roles with Amgen, Bristol Myers Squibb, Daiichi Sankyo, Genmab, Menarini Silicon Biosystems, Merck Serono-Pfizer, Merck Sharp & Dohme, Neracare, Novartis, Pierre Fabre, Provectus Biopharmaceuticals, Replimune, Sanofi, Sirius Medical, SkylineDx and 4SC and has received research funding from Amgen, Merck Serono-Pfizer and SkylineDx. G.V.L. is a consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer HealthCare Pharmaceuticals, BioNTech, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Evaxion Biotech A\/S, Fortiva Biologics, GI Innovation, Hexal AG (a Sandoz company), Highlight Therapeutics, IO Biotech, Immunocore Ireland Limited, Innovent Biologics, Iovance Biotherapeutics, Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec Medical Australia, PHMR Limited, Pierre Fabre, Regeneron Pharmaceuticals, Scancell Limited and SkylineDX. C.U.B. reports that he has received compensation for advisory roles from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures and Senya; has received research funding from Bristol Myers Squibb, Novartis, NanoString and 4SC; and is co-founder of Immagene. All compensations and funding for C.U.B. were paid to the institution, except for Third Rock Ventures and Immagene. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}